Perron Institute for Neurological and Translational Science

Nedlands, Western Australia WA 6009

1 studies enrolling now · 11 studies all time

What they study most

ALS, Amyotrophic Lateral Sclerosis, Hereditary Transthyretin-Mediated Amyloid Polyneuropathy, Huntington Disease, Inclusion Body Myositis, MSA, Multiple Sclerosis, Relapsing-Remitting, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), Parkinson Disease, Parkinson's Disease, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease — Recruiting now
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease — Running, not enrolling
• GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease — Running, not enrolling
• To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis — Completed
• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) — Stopped early
• NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy — Completed
• Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension — Stopped early
• Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure — Stopped early
• An Efficacy and Safety Study of Ravulizumab in ALS Participants — Stopped early
• Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure — Stopped early